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Dr John Ricotta (Washington, DC). Are you going to con-
tinue this study? I have a couple of questions. One is, what is the
sample size you would need to test the significance of your biomar-
ker assay? Do you know the sample size that you would need?
Dr Laura Capoccia. I think we surely are going to continue
our work. We are going to collect data from 100 patients, about 50
and 50 patients, and to analyze the continuous values because we
know that these biochemical markers have very low values to
detect. So we need more patients in order to have statistically
significant differences at continuous values analysis.
Dr Ricotta. Do you have plans to repeat the Mini-Mental
examination at 6 months or a year?
Dr Capoccia. Yes, it is our plan to repeat the test at 12
months.
Dr Joy Roy (Stockholm, Sweden). I wonder if using other
distal protection devices, such as the Parodi system, would affect
your results?
Dr Capoccia. We have chosen to use in all patients the same
device. It can be useful to have another arm of patients treated
with, for example, a Parodi or Moma or another device, and to
compare results.
Dr Wei Zhou (Palo Alto, Calif). The only psychometric test
you used was the Mini-Mental Status Exam. We too started
evaluating effects of microemboli on neuropsychological function.
Our neuropsychologist did not think only a Mini-Mental Status
Exam was adequate enough to evaluate neurocognitive function.
Our test battery has changed from 30 minutes to approximately 1
hour with a comprehensive neuropsychological evaluation. Would
you please comment on this?
Dr Capoccia. When planning our study, we had to decide
which test was better performing in our patients. We have chosen
the Mini-Mental test because it is quite simple for patients that, asyou can see, are old ones, so it is not so difficult to perform. And it
is quite simple to repeat at follow-up testing.
Dr Jacob Schneiderman (Ramat Gan, Israel). In your future
studies, would you correlate the incidence of cerebral microemboli
with the patient’s preoperative symptomatology, and with findings
of carotid plaque tissue characterization as obtained prior to revas-
cularization?
Dr Capoccia. The majority of our CAS patients, 95%, had
hyperechoic plaque composition. We actually don’t treat patients
with CAS if they have an anechoic plaque composition. In the
present series all our patients were asymptomatic and we recorded
no neurological complication but in the future we are going to
compare any eventual neurological complications with rate of
microembolization and so the diffusion-weighted results.
Dr Steve Merrell (Salt Lake City, Utah). This was an excel-
lent presentation. I just have a few questions about details of your
data. I realize your numbers are small, but can you tell us whether
the biomarkers were elevated specifically in the CAS patients that
had new ischemic lesions? And secondly, can you tell us about the
distribution of the new lesions in your CAS patients? How many
were ipsilateral versus bilateral relative to the CAS, and can you
share with us the number of new lesions that were identified in
these patients?
Dr Capoccia. Concerning the second question, I don’t have
the exact number of new lesions detected, but they were all
ipsilateral lesions. And I don’t remember the first question.
DrMerrell.Were the biomarkers elevated in the patients that
had the lesions on magnetic resonance?
Dr Capoccia. Yes. All patients with new ischemic lesion at
postoperative diffusion-weighted magnetic resonance had an ele-
vated and increasing level of the two biomarkers.
